Trial Profile

A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalcetrapib (Primary)
Indications Cardiovascular disorders; Coronary artery disease; Dyslipidaemias; Peripheral arterial disorders
Focus Registrational; Therapeutic Use
Acronyms dal-OUTCOMES 2
Sponsors Roche

01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
15 Aug 2012 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov.
07 May 2012 Status changed from recruiting to discontinued as reported by Roche.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com